Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-8993-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$580,000.00
Profitability
Miscellaneous
Employees39
Next Earnings Date11/19/2019 (Estimated)
OptionableOptionable
Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions
What is Vascular Biogenics' stock symbol?
Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."
How were Vascular Biogenics' earnings last quarter?
Vascular Biogenics Ltd (NASDAQ:VBLT) released its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The biopharmaceutical company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.25 million. Vascular Biogenics had a negative return on equity of 35.35% and a negative net margin of 3,021.20%. View Vascular Biogenics' Earnings History.
When is Vascular Biogenics' next earnings date?
What price target have analysts set for VBLT?
4 Wall Street analysts have issued 1 year price objectives for Vascular Biogenics' stock. Their predictions range from $2.00 to $3.00. On average, they anticipate Vascular Biogenics' stock price to reach $2.6667 in the next year. This suggests a possible upside of 110.0% from the stock's current price. View Analyst Price Targets for Vascular Biogenics.
What is the consensus analysts' recommendation for Vascular Biogenics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vascular Biogenics.
What are Wall Street analysts saying about Vascular Biogenics stock?
Here are some recent quotes from research analysts about Vascular Biogenics stock:
- 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (8/29/2019)
- 2. Chardan Capital analysts commented, "We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin." (5/16/2019)
- 3. HC Wainwright analysts commented, "We maintain our Buy rating of VBLT and our 12-month price target of $3.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple analysis applying a 6x multiple to our 2026 sales estimate discounted at 18%; and 2) price-earnings multiple analysis applying a 19x multiple to our 2026 estimated earnings discounted at 18%. (1) clinical; (2) regulatory; (3) commercial; (4) partnership; (5) financial; and (6) intellectual property." (1/15/2019)
Has Vascular Biogenics been receiving favorable news coverage?
Media headlines about VBLT stock have trended negative on Thursday, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Vascular Biogenics earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Vascular Biogenics.
Are investors shorting Vascular Biogenics?
Vascular Biogenics saw a decline in short interest in August. As of August 31st, there was short interest totalling 70,200 shares, a decline of 16.4% from the July 31st total of 84,000 shares. Based on an average daily volume of 46,500 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.3% of the shares of the stock are short sold. View Vascular Biogenics' Current Options Chain.
Who are some of Vascular Biogenics' key competitors?
Some companies that are related to Vascular Biogenics include Acasti Pharma (ACST), BioXcel Therapeutics (BTAI), Arcturus Therapeutics (ARCT), Axovant Gene Therapies (AXGT), Adamas Pharmaceuticals (ADMS), Generex Biotechnology (GNBT), REDHILL BIOPHAR/S (RDHL), Applied Therapeutics (APLT), Mustang Bio (MBIO), Newron Pharmaceuticals (NWPHF), Hookipa Pharma (HOOK), Sol Gel Technologies (SLGL), TAIWAN LIPOSOME/S (TLC), Aldeyra Therapeutics (ALDX) and Abeona Therapeutics (ABEO).
What other stocks do shareholders of Vascular Biogenics own?
Who are Vascular Biogenics' key executives?
Vascular Biogenics' management team includes the folowing people:
- Prof. Dror Harats, CEO & Director (Age 62)
- Mr. Amos Ron, CFO & Company Sec. (Age 64)
- Dr. Erez Feige, VP of Bus. Operations (Age 45)
- Dr. Eyal Breitbart, VP of Research & Operations (Age 52)
- Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 65)
Who are Vascular Biogenics' major shareholders?
Vascular Biogenics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CVI Holdings LLC (2.53%), Morgan Stanley (0.82%), Ladenburg Thalmann Financial Services Inc. (0.10%) and Athena Capital Advisors LLC (0.10%).
Which major investors are selling Vascular Biogenics stock?
VBLT stock was sold by a variety of institutional investors in the last quarter, including CVI Holdings LLC.
Which major investors are buying Vascular Biogenics stock?
VBLT stock was bought by a variety of institutional investors in the last quarter, including Athena Capital Advisors LLC, Morgan Stanley and Ladenburg Thalmann Financial Services Inc..
How do I buy shares of Vascular Biogenics?
Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vascular Biogenics' stock price today?
One share of VBLT stock can currently be purchased for approximately $1.27.
How big of a company is Vascular Biogenics?
Vascular Biogenics has a market capitalization of $45.57 million and generates $580,000.00 in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Vascular Biogenics employs 39 workers across the globe.View Additional Information About Vascular Biogenics.
What is Vascular Biogenics' official website?
How can I contact Vascular Biogenics?
Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]
MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
